Dr. Richard Heinzl reports

ASEP MEDICAL HOLDINGS INC. WELCOMES MR. THOMAS O'SHAUGHNESSY TO THE BOARD OF DIRECTORS

Asep Medical Holdings Inc. has appointed Thomas O'Shaughnessy to its board of directors. The appointment takes effect immediately.

Mr. O'Shaughnessy is the chief executive officer of Onco-Innovations Ltd., a Canadian-based biotechnology company dedicated to cancer research and treatment, specializing in oncology. He is also the founder and managing principal of Carnarvon Health Industry Solutions Inc., a health and life sciences consultancy firm. Throughout his extensive career, he has worked with some of the largest health organizations and systems in Canada and globally on assignments from business and technology strategy development and execution to strategic management, digital health implementation, and senior stakeholder engagement. A trusted adviser for high-stakes transformation initiatives and mission-critical implementation programs, he leads high performance organizations and teams on a national scale.

"I am honoured to take on this role with the Asep team and look forward to building momentum for both the sepsis diagnostic technology and the anti-biofilm peptide. As a former Asep advisory board member, I understand the company's incredible potential and I am eager to contribute to its future success," said Mr. O'Shaughnessy.

"We are very pleased to welcome Mr. O'Shaughnessy to the Asep board of directors," commented Dr. Richard Heinzl, Asep's interim chief executive officer and fellow board member. "His depth of industry and leadership experience will make an immediate impact on the company, and we look forward to reaping the rewards of his strategic and operational expertise," Dr. Heinzl added.

About Asep Medical Holdings Inc.

Asep Medical is a standout biotechnology research and development company based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E.W. Hancock, one of the world's foremost microbiologists. Asep holds a controlling interest in two private subsidiary companies -- Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

We seek Safe Harbor.